CJC-1295 No DAC + Ipamorelin: Understanding the 20mg Research Blend

A CJC-1295 No DAC 10mg + Ipamorelin 10mg preparation is a two-component research blend containing a total nominal peptide content of 20mg. It combines two chemically distinct research materials associated with different receptor pathways: a modified GHRH(1-29)-type analogue and the growth-hormone-secretagogue pentapeptide ipamorelin.

The most important scientific point is that this formulation is not one 20mg peptide. It is a fixed 1:1 blend consisting of 10mg of one component plus 10mg of another. Composition, identity, purity and quantity therefore need to be considered at both the blend level and the individual-component level.

What Does the 20mg Blend Contain?

  • CJC-1295 No DAC: 10mg nominal content.
  • Ipamorelin: 10mg nominal content.
  • Total nominal peptide content: 20mg.
  • Nominal ratio: 1:1 by labelled mass.

This should not be confused with products described as a “10mg CJC/Ipamorelin blend” where the 10mg may represent the combined total, for example 5mg + 5mg. Clear component-level labelling prevents that ambiguity.

Why the Two Components Are Scientifically Different

CJC-1295 No DAC and ipamorelin are often grouped together in marketplace terminology because both are discussed in growth-hormone research. Mechanistically, however, they are not the same class of peptide.

CJC-1295 No DAC / Modified GRF (1-29)

This term is widely used for a modified GHRH(1-29)-type research analogue without the albumin-binding Drug Affinity Complex. The relevant receptor pathway is the GHRH receptor.

Ipamorelin

Ipamorelin, also referenced as NNC-26-0161, is a synthetic pentapeptide classified as a growth-hormone secretagogue. Its research pharmacology is associated primarily with the growth-hormone-secretagogue/ghrelin receptor (GHSR).

Because the components act through different receptor systems, a combined preparation is best documented as a two-pathway research mixture rather than described generically as one “GH peptide”.

Does Combining Two Pathways Prove Synergy?

No. A mechanistic rationale for studying two signalling pathways together does not establish that a fixed blend has clinically proven synergy. The exact 10mg + 10mg commercial-style formulation does not have a robust controlled clinical evidence base demonstrating that the mixture produces a specific combined outcome.

Scientific interpretation should therefore separate component evidence from blend evidence. Published research on GHRH fragments or ipamorelin can explain the biology of each component, but it should not be presented as if the exact fixed-ratio blend itself was the subject of those studies.

Component Evidence: CJC-1295 No DAC

Human research with GHRH(1-29)-NH2 and defined analogues established that the N-terminal 29-residue region can retain GHRH activity. Separately, clinical research with long-acting CJC-1295 demonstrated sustained effects when an albumin-binding DAC was present.

The DAC study should not be used to assign a multi-day half-life to the No-DAC component in this blend. For the detailed nomenclature and evidence distinction, see What Is CJC-1295 No DAC? and CJC-1295 No DAC vs CJC-1295 With DAC.

Component Evidence: Ipamorelin

Ipamorelin was described in peer-reviewed pharmacology as a selective growth-hormone secretagogue and later studied in healthy human volunteers using PK/PD modelling. Published human data showed a short terminal half-life under intravenous study conditions and an episodic measured GH response.

A later randomized Phase II postoperative-ileus trial did not show a statistically significant advantage over placebo on its key efficacy endpoints, illustrating why component pharmacology should not be converted into broad claims of clinical effectiveness.

For a full review, see What Is Ipamorelin?.

Why Blend Analysis Is More Complex Than Single-Peptide Analysis

In a single-component preparation, the main analytical objective is often to confirm one target peptide and assess related impurities. In a two-component blend, there are already two intended analytes before any impurity is considered.

A chromatogram may therefore contain separate signals from both intended peptides, depending on whether the analytical method resolves them. Additional peaks may represent impurities, degradants or other sample components. A single headline “purity” figure can be misleading if it does not explain how both intended compounds were identified and quantified.

HPLC Considerations for a Two-Component Blend

Reverse-phase HPLC can be useful when a method separates CJC-1295 No DAC and ipamorelin sufficiently to permit meaningful peak assignment. Method suitability becomes critical because the intended components have different structures and may interact differently with the stationary phase.

A useful chromatographic report should make clear:

  • whether both intended components were resolved;
  • how each peak was identified;
  • whether peak-area purity is reported per component or for the preparation as a whole;
  • what detection conditions were used; and
  • whether co-elution limits interpretation.

See Understanding HPLC Purity for the broader principles.

LC-MS and Orthogonal Identity Testing

Mass spectrometry can provide complementary evidence by associating separated peaks with mass-to-charge information. For a blend, this can help distinguish the two intended molecular species rather than inferring identity from retention time alone.

Where the research objective requires quantitative confirmation of a 10mg + 10mg formulation, identity evidence and quantitative content testing should be treated as separate questions. A peak can be correctly identified without proving the labelled quantity, and a purity percentage is not the same measurement as total content.

Why the 10mg + 10mg Label Matters

Marketplace blend names frequently create ambiguity. “20mg blend” may tell a laboratory the total content but not the component distribution. Conversely, “CJC/Ipamorelin 10mg” could be interpreted as 10mg of each component or 10mg total.

The clearest record states all three values: CJC-1295 No DAC 10mg + Ipamorelin 10mg = 20mg total. That wording should be repeated consistently across the batch record, COA and laboratory inventory.

Certificate of Analysis for a Blend

A blend COA should ideally identify the complete formulation and the production batch. Where available, analytical documentation should distinguish the component identities rather than supplying a report for only one ingredient.

Researchers reviewing a blend can ask:

  • Does the COA name both components?
  • Does it state the intended 10mg + 10mg composition?
  • Can both components be identified analytically?
  • Is there quantitative evidence for each component where required?
  • Does the batch identifier match the physical vial?

For more information, see Certificate of Analysis Explained and the COA Library.

Common Interpretation Errors

Assuming 20mg means 20mg of each peptide

It does not. In this formulation 20mg is the combined nominal content: 10mg + 10mg.

Using DAC pharmacokinetics for the No-DAC component

The multi-day CJC-1295 human data relate to the DAC-containing molecule and should not be transferred to CJC-1295 No DAC.

Calling the blend one molecule

It contains two separate peptides with separate molecular identities.

Claiming proven synergy

Different receptor pathways provide a mechanistic reason for combined experimental investigation, but that is not equivalent to controlled evidence for the exact commercial blend.

Frequently Asked Questions

What is another common name for the CJC component?

Modified GRF (1-29) or Mod GRF (1-29) is commonly used for the No-DAC research material.

What is another identifier for Ipamorelin?

NNC-26-0161 is a research/development identifier associated with ipamorelin.

Is this a 1:1 blend?

Yes, based on the stated nominal masses: 10mg of each component.

Can one HPLC purity number verify the entire blend?

Not necessarily. Interpretation depends on whether both intended components are resolved, identified and quantified under a suitable method.

Selected Scientific References

Related Research Resources

This article is provided for laboratory, analytical and scientific education only. It does not provide dosing, administration, injection, therapeutic or personal-use guidance.

Back to blog